![]() |
| This immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. Image Credit: Allen Lab, NCI/NIH. |
Most cancers are thought to evade the immune system. These cancers don’t carry very many mutations, and they aren’t infiltrated by cancer-fighting immune cells. Scientists call these cancers immunologically “cold.”
Now new research suggests such cancers aren’t as “cold” as once thought. Researchers from the La Jolla Institute for Immunology (LJI), UC San Diego Moores Cancer Center, and UC San Diego, have found that patients with “cold” tumors actually do make cancer-fighting T cells.
This discovery opens the door to developing vaccines or therapies to increase T cell numbers and treat many more types of cancer than currently thought possible.
“In virtually every patient we’ve looked at, with every kind of cancer we’ve analyzed, we can detect pre-existing natural immunity against their tumor’s immunogenic subset of mutations known as neoantigens,” says LJI Professor Stephen Schoenberger, Ph.D., who co-led the new study with LJI Professor Bjoern Peters, Ph.D. “Therefore, we think these patients may actually benefit from empowering this response through personalized immunotherapy.”
“Every cancer patient is different,” adds Peters. “But this research is an important step toward finding immune cell targets relevant for individual patient tumors.”


.jpg)

.jpg)


.jpg)
.jpg)




.jpg)
.jpg)